UOC
TCRR

UBS O'Connor’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

UBS O'Connor’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-54,035
Closed -$97K – 882
2022
Q3 		$97K Buy
+54,035
New +$157K ﹤0.01% 852

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

UBS O'Connor's TCRR Position: Q4 2022 in Review

UBS O'Connor sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2022, closing a stake of 54,035 shares — an estimated $97K sold.

UBS O'Connor first reported a position in TCRR in Q3 2022 and held it in 1 quarter. The position peaked at $97K in Q3 2022. 62 funds tracked by Wall St. Rank hold TCRR as of Q4 2022.

  • UBS O'Connor reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • UBS O'Connor sold 54,035 TCR2 Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $97K.
  • UBS O'Connor first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • UBS O'Connor's TCR2 Therapeutics Inc. Common Stock position peaked at $97K in Q3 2022.
  • 62 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2022.

Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.